Controlled release of FGF-2 using fragmin/protamine microparticles and effect on neovascularization

Journal of Biomedical Materials Research - Part A

Volumn 91, Issue 3, 2009, Pages 814-823

  Nakamura, Shingo ^a   Kanatani, Yasuhiro ^a   Kishimoto, Satoko ^a   Nakamura, Shin Ichiro ^a   Ohno, Chizuko ^a   Horio, Takuya ^a   Masanori, Fujita ^a   Hattori, Hidemi ^a   Tanaka, Yoshihiro ^a   Kiyosawa, Tomoharu ^a   Maehara, Tadaaki ^a   Ishihara, Masayuki ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Complex formation; Fibroblast growth factor 2 (FGF 2); Fragmin protamine microparticles; Stabilization; Vascularization

Indexed keywords

COMPLEX FORMATION; CONTROLLED RELEASE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR-2 (FGF-2); FIBROUS TISSUE; FRAGMIN/PROTAMINE MICROPARTICLES; HIGH AFFINITY; LOW-MOLECULAR WEIGHT HEPARINS; MICRO-PARTICLES; NEOVASCULARIZATION; SLOW DIFFUSION; VASCULARIZATION;

BIOACTIVITY; BIOCHEMISTRY; CELL CULTURE; DEGRADATION; FIBROBLASTS; MICROBIOLOGY; PEPTIDES; POLYSACCHARIDES; STABILIZATION;

BIODEGRADATION;

DALTEPARIN; FIBROBLAST GROWTH FACTOR 2; PROTAMINE; RECOMBINANT BASIC FIBROBLAST GROWTH FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BIODEGRADATION; CAPILLARY DENSITY; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN IMMOBILIZATION; PROTEIN STABILITY; THERMOSTABILITY;

ANIMALS; BIODEGRADATION, ENVIRONMENTAL; DALTEPARIN; DIFFUSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FIBROBLAST GROWTH FACTOR 2; HUMANS; KINETICS; MALE; MICE; MICROSPHERES; NEOVASCULARIZATION, PATHOLOGIC; PROTAMINES; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TEMPERATURE;

EID: 70350348386     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.32265     Document Type: Article

References (33)

1. Stocum DL. Frontiers in medicine: Regeneration. Science 1997;276:59-87.
2. Gospodarowicz D. Fibroblast growth factor and its involvement in developmental processes. Curr Top Dev Biol 1990;24:57-93.
3. Tabata Y, Ikada Y. Vascularization effect of basic fibroblast growth factor released from gelatin hydrogels with different biodegradabilities. Biomaterials 1999;20:2169-2175. (Pubitemid 29488666)
4. Slack JM, Darlington BG, Heath JK, Godsave SF. Mesoderm induction in early Xenopus embryos by heparin binding growth factors. Nature 1987;326:197-200.
5. Abraham JA, Mergia J, Whang L, Tumolo A, Friedman J, Hjerrild KA, Gospodarowicz D, Fiddes JC. Nucleotide sequence of a bovine clone encoding the angiogenic protein, basic fibroblast growth factor. Science 1986;233:545-548.
6. Canalis E, Centrella M, McCarthy T. Effects of basic fibroblast growth factor on bone formation in vitro. J Clin Invest 1988;81:1572-1577. (Pubitemid 18131626)
7. Nakajima F, Ogasawara A, Goto K, Moriya H, Ninomiya Y, Einhorn TA, Yamazaki M. Spatial and temporal gene expression in chondrogenesis during fracture healing and the effects of basic fibroblast growth factor. J Orthop Res 2001;19:935-944. (Pubitemid 32799085)
8. Tsuboi R, Rifkin DB. Recombinant basic fibroblast growth factor stimulates wound healing in healing-impairing db/db mice. J Exp Med 1990;172:245-251. (Pubitemid 20217266)
9. Ishihara M, Ono K. Structure and function of heparin and heparan sulfate: Heparinoid library and modification of FGF-activities. Trends Glycosci Glycotech 1998;10:223-233. (Pubitemid 128094328)
10. Ishihara M. Biosynthesis, structure, and biological activity of basic FGF binding domains of heparan sulfate. Trends Glycosci Glycotech 1993;5:343-354. (Pubitemid 24776835)
11. Salmivirta M, Lidholt K, Lindahl U. Heparan sulfate: a piece of information. FASEB J 1996;10:1270-1279.
12. Lindahl U, Lidholt K, Spillmann D, Kjellen L. More to "heparin" than anti-coagulation. Thromb Res 1994;75:1-32.
13. Ishihara M, Sato M, Hattori H, Saito Y, Yura H, Ono K, Masuoka K, Kikuchi M, Fujikawa K, Kurita A. Heparin-carrying polystyrene (HCPS)-bound collagen substratum to immobilize heparin-binding growth factors and to enhance cellular growth. J Biomed Mater Res 2001;56:536-544. (Pubitemid 32611215)
14. Tanihara M, Suzuki Y, Yamamoto E, Noguchi A, Mizushima Y. Sustained release of basic fibroblast growth factor and angiogenesis in a novel covalently crosslinked gel of heparin and alginate. J Biomed Mater Res 2001;56:216-222. (Pubitemid 32520696)
15. Ishihara M, Obara K, Ishizuka T, Fujita M, Sato M, Masuoka K, Saito Y, Yura H, Matsui T, Hattori H, Kikuchi M, Kurita A. Controlled release of fibroblast growth factors and heparin from photocrosslinked chitosan hydrogels and subsequent effect on in vivo vascularization. J Biomed Mater Res A 2003;64:551-559. (Pubitemid 37522496)
16. Fujita M, Ishihara M, Shimizu M, Obara K, Ishizuka T, Saito Y, Yura H, Morimoto Y, Takase B, Matsui T, Kikuchi M, Maehara T. Vascularization in vivo caused by the controlled release of fibroblast growth factor-2 from an injectable chitosan/non-anticoagulant heparin hydrogel. Biomaterials 2004;25:699-706. (Pubitemid 37357283)
17. Nakamura S, Ishihara M, Obara K, Masuoka K, Ishizuka T, Kanatani Y, Takase B, Matsui T, Hattori H, Sato T, Kariya Y, Maehara T. Controlled release of fibroblast growth factor-2 from injectable 6-O-desulfated heparin hydrogel and subsequent effect on in vivo vascularization. J Biomed Mater Res A 2006;78:364-371.
18. Tae G, Kim YJ, Choi WI, Kim M, Stayton PS, Hoffman AS. Formation of a novel heparin-based hydrogel in the presence of heparin-binding. Biomacromolecules 2007;8:1979-1986.
19. Pike DB, Cai S, Pomraning KR, Firpo MA, Fisher RJ, Shu XZ, Prestwich GD, Peattie RA. Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. Biomaterials 2006;27:5242-5251. (Pubitemid 44080293)
20. Yamaguchi N, Kiick KL. Polysaccharide-poly(ethylene glycol) star copolymer as a scaffold for the production of bioactive hydrogels. Biomacromolecules 2005;6:1921-1930.
21. Yamaguchi N, Zhang L, Chae BS, Palla CS, Furst EM, Kiick KL. Growth factor mediated assembly of cell receptor-responsive hydrogels. J Am Chem Soc 2007;129:3040-3041. (Pubitemid 46449311)
22. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C. Heparin and low-molecular heparin, mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S. (Pubitemid 32154195)
23. Wolzt M, Wetermann A, Nieszpaur-Los M, Schneider B, Fassolt A, Lechner K, Eichler H, Kyrle PA. Studies on the neutralizing of protamine on unfractionated and low-molecular-weight heparin (FragmineR) at the site of activation of the coagulation system in man. Thromb Haemost 1995;73:439-443.
24. Pan M, Lezo JS, Medina A, Romero M, Hernandez E, Segura J, Melian F, Wanguemert F, Landin M, Benitez F, Amat M, Velasco F, Torres A. In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation. Am J Cardiol 1997;80:1336-1338. (Pubitemid 27513336)
25. Masuoka K, Ishihara M, Asazuma T, Hattori H, Matsui T, Takase B, Kanatani Y, Fujita M, Saito Y, Yura H, Fujikawa K, Nemoto K. The interaction of chitosan with fibroblast growth factor-2 and its protection from inactivation. Biomaterials 2005;26:3277-3284. (Pubitemid 39647261)
26. Nakamura S, Nambu M, Kishimoto S, Ishizuka T, Hattori H, Kanatani Y, Takase B, Aoki H, Kiyosawa T, Maehara T, Ishihara M. Effect of controlled release of fibroblast growth factor-2 from chitosan/fucoidan micro complex hydrogel on in vitro and in vivo vascularization. J Biomed Mater Res A 2008;85:619-627. (Pubitemid 351632873)
27. Ishiyama M, Tominaga H, Shiga M, Sasamoto K, Ohkura Y, Ueno K. A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet. Biol Pharm Bull 1996;19:1518-1520. (Pubitemid 26403266)
28. Gospodarowicz D, Cheng J. Heparin protects basic and acidic FGF from inactivation. J Cell Physiol 1986;128:475-484. (Pubitemid 16015532)
29. Isha-Michaeli R, Elder A, Vlodarsky I. Heparanase activity expressed by platelets, neutrophils, and lymphoma cells releases active fibroblast growth factor from extracellular matrix. Cell Regul 1990;1:833-842.
30. Zhang L, Furst EM, Kiick KL. Manipulation of hydrogel assembly and growth factor delivery via the use of peptidepolysaccharide interactions. J Control Release 2006;114:130-142. (Pubitemid 44291851)
31. Seal BL, Panitch A. Physical polymer matrices based on affinity interactions between peptides and polysaccharides. Biomacromolecules 2003;4:1572-1582. (Pubitemid 37455568)
32. Patil SD, Papadmitrakopoulos F, Burgess DJ. Concurrent delivery of dexamethasone and VEGF for localized inflammation control and angiogenesis. J Control Release 2007;117:68-79. (Pubitemid 46164863)
33. Bijsterveld NR, Hettiarachchi R, Peter R, Prins MH, Levi M, Buller HR. Low-Molecular weight heparins in venous and arterial thrombotic disease. Thromb Haemost 1999;82:139-147. (Pubitemid 30093651)